Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bridges

Showing results (381-390 of 403) with videos related to

Pageof 41
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 27, 2017
Optimization of M<sub>4</sub> positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacologyBruce J Melancon, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience|April 22, 2018
Discovery and Optimization of Potent and CNS Penetrant M<sub>5</sub>-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide ScaffoldAaron M Bender, Hyekyung P Cho, Kellie D Nance, et al.
Journal of Medicinal Chemistry|August 10, 2019
A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit QualificationPaul Bamborough, Chun-Wa Chung, Emmanuel H Demont, et al.
Bioorganic & Medicinal Chemistry Letters|October 18, 2015
Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulatorsChrysa Malosh, Mark Turlington, Thomas M Bridges, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Discovery of VU0467485/AZ13713945: An M<sub>4</sub> PAM Evaluated as a Preclinical Candidate for the Treatment of SchizophreniaMichael R Wood, Meredith J Noetzel, Bruce J Melancon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2012
The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5Ryan D Morrison, Anna L Blobaum, Frank W Byers, et al.
Bioorganic & Medicinal Chemistry Letters|May 23, 2019
VU6005806/AZN-00016130, an advanced M<sub>4</sub> positive allosteric modulator (PAM) profiled as a potential preclinical development candidateDarren W Engers, Bruce J Melancon, Allison R Gregro, et al.
Journal of Medicinal Chemistry|July 10, 2015
Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain InhibitorsEmmanuel H Demont, Chun-wa Chung, Rebecca C Furze, et al.
ACS Medicinal Chemistry Letters|July 10, 2015
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting SchizophreniaSusana Conde-Ceide, Carlos M Martínez-Viturro, Jesús Alcázar, et al.
Pageof 41

Showing results (381-390 of 403) with videos related to

Sort By:
Pageof 41
Bioorganic & Medicinal Chemistry Letters|April 27, 2017
Optimization of M<sub>4</sub> positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacologyBruce J Melancon, Michael R Wood, Meredith J Noetzel, et al.
ACS Chemical Neuroscience|April 22, 2018
Discovery and Optimization of Potent and CNS Penetrant M<sub>5</sub>-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide ScaffoldAaron M Bender, Hyekyung P Cho, Kellie D Nance, et al.
Journal of Medicinal Chemistry|August 10, 2019
A Qualified Success: Discovery of a New Series of ATAD2 Bromodomain Inhibitors with a Novel Binding Mode Using High-Throughput Screening and Hit QualificationPaul Bamborough, Chun-Wa Chung, Emmanuel H Demont, et al.
Bioorganic & Medicinal Chemistry Letters|October 18, 2015
Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulatorsChrysa Malosh, Mark Turlington, Thomas M Bridges, et al.
ACS Pharmacology & Translational Science|August 23, 2021
Discovery of the First Selective M<sub>4</sub> Muscarinic Acetylcholine Receptor Antagonists with <i>in Vivo</i> Antiparkinsonian and Antidystonic EfficacyMark S Moehle, Aaron M Bender, Jonathan W Dickerson, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Discovery of VU0467485/AZ13713945: An M<sub>4</sub> PAM Evaluated as a Preclinical Candidate for the Treatment of SchizophreniaMichael R Wood, Meredith J Noetzel, Bruce J Melancon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 20, 2012
The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5Ryan D Morrison, Anna L Blobaum, Frank W Byers, et al.
Bioorganic & Medicinal Chemistry Letters|May 23, 2019
VU6005806/AZN-00016130, an advanced M<sub>4</sub> positive allosteric modulator (PAM) profiled as a potential preclinical development candidateDarren W Engers, Bruce J Melancon, Allison R Gregro, et al.
Journal of Medicinal Chemistry|July 10, 2015
Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain InhibitorsEmmanuel H Demont, Chun-wa Chung, Rebecca C Furze, et al.
ACS Medicinal Chemistry Letters|July 10, 2015
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting SchizophreniaSusana Conde-Ceide, Carlos M Martínez-Viturro, Jesús Alcázar, et al.
Pageof 41